• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tidepool founder and CEO is stepping down

April 11, 2025 By Sean Whooley

Howard Look Tidepool (1)Howard Look announced that he is stepping down from his role as CEO at automated insulin delivery technology developer Tidepool.

Look, who co-founded the Palo Alto, California-based company in 2013, shared the news on LinkedIn.

“After 12 incredible years, I’m stepping back from my role as CEO of Tidepool,” he wrote. “It’s hard to put into words what this journey has meant to me. I’m deeply proud of all that we’ve accomplished together—from big regulatory milestones to the impact we’ve had in the diabetes community.”

Look said that co-founder and longtime partner, Brandon Arbiter, steps into the role of acting CEO. He plans to continue serving on Tidepool’s board as a strategic advisor and support Arbiter and the team.

Tidepool, a non-profit diabetes data management group, developed the FDA-cleared Tidepool Loop, a “do-it-yourself,” (DIY) automated insulin delivery (AID) system. The hybrid, closed-loop AID app has compatibility with multiple insulin pumps and continuous glucose monitors. Recent collaborations include integrations with Abbott and Sequel Med Tech, among others.

Dr. Robert Gabbay, a longtime diabetes expert who recently served as chief scientific and medical officer of the ADA, said on LinkedIn that Look “had an extraordinary impact on people with diabetes.”

“I can say he has always been a most generous, genuine, passionate, brilliant person not afraid to do the unconventional to improve the lives of people with diabetes,” Gabbay wrote.

Tidepool posted on the social media site as well: “Change is never easy, especially when it involves someone who means so much to our community. Howard Look, Tidepool’s founder and guiding force, is stepping back from his role as CEO to focus on his health.

“While this news is difficult, we are committed to carrying forward the vision and mission he built with all of us.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Technology

IN CASE YOU MISSED IT

  • Embecta expands partnership with Direct Relief to support diabetes initiatives on World Diabetes Day
  • What diabetes tech companies are doing on World Diabetes Day 2025
  • Dexcom unveils new advocates to support World Diabetes Day campaign
  • Renu MedTech introduces tubeless insulin patch pump in India
  • ViCentra highlights diabetes in the workplace on World Diabetes Day

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS